42results about How to "Improve the effectiveness of treatment" patented technology

Hypotonic formulations were evaluated for delivering water-soluble drugs and for drug delivery with muco-inert (that is, non-adhesive) mucus-penetrating nanoparticles (MPP). Hypotonic formulations markedly increased the rate at which drugs and MPP reached the epithelial surface, including deep into the vaginal folds. Minimally hypotonic formulations, preferably ranging from 20-220 mOsm / kg, provided rapid and uniform delivery of MPP to the entire vaginal surface, with minimal risk of epithelial toxicity. Data also show that there is a higher osmolality in the colon, such that vehicles with an osmolality above that of blood plasma (generally considered isotonic at ˜300 mOsm / kg), still lead to improvements in distribution in the colon due to rapid, osmotically-induced fluid absorption. The range for improved colon distribution with a hypotonic vehicle in the colon is ˜20 mOsm / kg-450 mOsm / kg.

Methods and devices producing time varying magnetic field treats a patient. The device contains a coil made of insulated wires, an energy storage device, an energy source and a switch. The coil is flexibly attached in a case. The device has at least one blower for cooling the coil. The methods and devices can be used in for example in physiotherapy, neuropsychiatric therapy, aesthetic therapy, urology or urogynecology.

A non-linear shaped charge perforator for use in perforating an oil and gas formation into which a wellbore has been drilled comprises a monolithic, axisymmetric metal case in which is disposed a main explosive charge between the front of the case, which is closed with a concave metal liner, and the closed back end of the case. The main explosive charge contains multiple initiation points, preferably two initiation points located about 180° apart on the outside surface of the charge, so that when the perforator is detonated the main charge is initiated such that the metal liner is collapsed into a non-circular jet, preferably a fan-shaped jet, that pierces the casing of the wellbore and forms non-circular perforations, preferably slot-shaped perforations, in the surrounding formation.

Combined methods for treating a patient using time-varying magnetic field are described. The treatment methods combine various approaches for aesthetic treatment. The methods are focused on enhancing a visual appearance of the patient.

Methods for treating a patient using time varying magnetic field are described. The treatment methods combine various approaches for aesthetic treatment. The methods are focused on enhancing a visual appearance of the patient.

Methods for treating a patient using a time varying magnetic field are described. The treatment methods combine various approaches for aesthetic treatment. The methods are focused on enhancing a visual appearance of the patient. An exemplary method includes charging an energy storage device and discharging the energy storage device to a magnetic field generating device to generate the time-varying magnetic field. The time-varying magnetic field is applied to the patient.

The invention provides a biological dressing for treatment of a dermatological disease comprised of a gum resin, a topically acceptable volatile solvent, and a pharmacologically active agent. The gum resin is present in a suitable amount that the composition, when the solvent evaporates, will dry to form a solid coating that sticks to the skin or mucosal membrane to which the composition is applied and maintain the pharmacologically active agent over a sustained period of time in contact with sites on the skin or mucosal membranes exhibiting symptoms of the disease. Methods are provided for treating symptoms of dermatological diseases with such a pharmacological composition. Biological dressings including tincture of benzoin and clotrimazole are shown to be efficacious for the long-term amelioration of symptoms of athlete's foot.

The invention belongs to the field of biological medicines, and relates to application of Bcl-xL inhibitor and oncolytic virus to preparation of anti-tumor medicines. It is found for the first time that Bcl-xL inhibitor can be used for preparing oncolytic virus anti-tumor synergist. The invention meanwhile relates to a pharmaceutical composition containing Bcl-xL inhibitor and oncolytic virus, a medicine suit containing Bcl-xL inhibitor and oncolytic virus, and application of Bcl-xL inhibitor and oncolytic virus to treatment of tumors, especially tumors not sensitive to oncolytic virus.

The invention belongs to the field of biomedicine and relates to synergistic antitumor drug, in particular to application of antitumor drug like DNA-PK (DNA-dependent protein kinase, DNA-PK) inhibitors and oncolytic viruses in preparing antitumor drug. It is found for the first time that the antitumor drug like the DNA-PK inhibitor with various targets can be used for preparing oncolytic virus antitumor synergists. The invention further relates to a drug composition containing the antitumor drug and the oncolytic viruses, drug sets comprising the antitumor drug and the oncolytic viruses and application of the antitumor drug and the oncolytic viruses in treating tumor, especially for tumor insensitive to the oncolytic viruses.

Methods and devices create an intestinal braking effect, are non-invasive or minimally invasive, and may be reversible. These methods and devices are accomplished via stabilized implantable systems, and ingestible pills. In one embodiment, the implantable system comprises a device delivering a therapeutic substance to a target location within the gastrointestinal tract of a patient in order to initiate an intestinal braking effect which would promote sensations of satiety and stimulate excess weight loss for the patient.

The invention discloses application of EZH2 (enhancer of zeste homolog 2) inhibitor compounds in the preparation of drugs for treating eye melanoma; the EZH2 inhibitor compounds include GSK503, GSK343, EPZ005687 and EPZ-6438, having molecular formulas of C31H38N6O2, C31H39N7O2, C34H44N4O4 and C32H37N5O3, and molecular structural formulas which are shown in the description. The invention is intended to provide novel targets and drugs for the clinical treatment of eye melanoma, treatment effectiveness is improved, eye ball extraction rate is reduced, vision prognosis of patient is improved, and a novel field is exploited unprecedentedly.

The invention discloses a switching device for composite radio frequency and irreversible electroporation. The switching device for the composite radio frequency and the irreversible electroporation comprises an alternating current and direct current switching module and a current sensor switching module and is used for outputting high-voltage direct current pulses for irreversible electroporation and radio frequency sine waves output by radio frequency ablation to two external electrode interfaces in a time-sharing switching mode, the switching device is respectively connected with the output of a DCAC inverter circuit of the radiofrequency ablation module, a high-voltage direct current output of a irreversible electroporation module, a control interface of a main control board and a electrode interface. Compared with the prior art, ablation working modes can be switched according to needs, irreversible electroporation ablation treatment is carried out, and needle passage ablation can be carried out through low-power ablation mode output when irreversible electroporation ablation treatment is finished. The switching device can be used for common focuses as a radiofrequency ablation host. The treatment effectiveness of the irreversible electroporation equipment is improved, a compound treatment mode of irreversible electroporation and radiofrequency ablation can be carried out on some complex cases, and the clinical application range of the device is greatly widened.

This invention relates to a pharmaceutical composition having saikosaponin as a main component, the use of the pharmaceutical composition, as well as the preparation method thereof, wherein the pharmaceutical composition is used to prevent or treat the infection of one virus selected from the hepatitis C virus, the measles virus, the respiratory syncytial virus, the vesicular stomatitis virus, the dengue virus, and the non-enveloped viruses.

The invention discloses an application of a ubiquitin-binding enzyme E2 inhibitor as an anti-tumor synergist / drug resistance reversal agent of oncolytic virus for the first time. The ubiquitin-bindingenzyme E2 inhibitor can significantly enhance the oncolytic effect of oncolytic virus by inhibiting ubiquitin-binding enzyme E2. The compound Bay11-7082 for inhibiting the activity of the ubiquitin-binding enzyme E2 to act on tumor cells in cooperation with oncolytic virus, especially M1 virus, and experimental results show that Bay11-7082 can be cooperated with oncolytic virus to enhance the anti-tumor effect.

Peptides having antimicrobial properties are described herein, as are compositions containing such peptides, and methods for using the peptides.

The present invention provides a diagnostic imaging system (100), comprising a magnetic resonance (MR) imaging system (110) for providing an image representation of at least a portion of a subject of interest (120) positioned in an examination space (116), a hyperthermia device (111) for locally heating a target zone within the portion of the subject of interest (120), and a control unit (126) for controlling the MR imaging system (110) and the hyperthermia device (111), wherein the diagnostic imaging system (100) is adapted to provide a diagnostic image representation of the portion of the subject of interest (120) by correlating image representations obtained at different temperatures of the target zone, wherein the diagnostic image representation comprises information on temperature dependent changes of the metabolism of the subject of interest (120). The invention further provides a treatment system comprising the above diagnostic imaging system (100), a treatment module (146) for applying a treatment to the subject of interest (120) for destroying cells within the target zone, and a control module (126) for controlling the treatment module (146) for applying the treatment based on diagnostic image representations obtained by the diagnostic imaging system (100). Accordingly, changes of the metabolism of the subject of interest can be evaluated to direct a treatment to such areas, where the cells have not yet been destroyed as desired. By comparing the difference of the above measurements between the first and the second temperature, the efficiency of the treatment can be evaluated and the further treatment can be adapted based on the metabolism changes.

The invention finds that metformin can obviously inhibit the growth of eye melanoma cells, and the drug action effect is increased along with the increase of the concentration. The invention aims at providing a new clinical treatment medicine for the eye melanoma, improving the treatment effectiveness, prolonging the life of a patient and improving the life quality, so that a new field of applying the metformin to the treatment of the eye melanoma is developed.

Embodiments of the present invention include an apparatus and method for treatment of pain by a device that provides transcutaneous electrical nerve stimulation. The device includes an applicator equipped with an electric pulse provider that sends an electric pulse to a set of electrodes disposed in an applicator head. The device is placed onto the skin of a patient's body at the point where the patient experiences pain and such that the electrodes of the device contact the skin of the patient while an insulating land area between the electrodes compresses the nerve during transmittal of the electric pulse through the electrodes and into the patient's body.

The invention relates to the field of anticancer medicines and particularly discloses an application of a CTCF snare protein in preparation of an anti-uveal melanoma medicine. The CTCF snare protein is an artificially expressed recombinant protein, wherein N-terminal and C-terminal functional zones of a wild-type CTCF are removed, while a zinc finger structure ZF is remained and DNA methylase Sss1 is added. A researching result proves that by transferring the CTCF snare in an UM cell, growth and metastasis of the uveal melanoma can be effectively inhibited. The CTCF snare protein provides a new target point and a therapy medicine for clinical treatment of the uveal melanoma, improves therapy validity, reduces rate of eyeball removal, and improves visional prognosis of patients.

The invention relates to a modular stent with branches for treating thoracoabdominal aortic aneurysm, and belongs to the technical field of medical instruments. The stent is a covered stent and comprises a descending aorta region near-end anchoring module, a visceral artery region branch graft module and an abdominal aorta region far-end anchoring module which are communicated in sequence; the number of the descending aorta area near-end anchoring module is at least one. The invention provides a modular endovascular graft with branches for treating thoracico-abdominal aortic aneurysm of Asian people. Through modularization and different combination modes, anatomical structures of various thoracico-abdominal aortic aneurysms can be adapted, and the time required by customization can be effectively avoided; visceral arteries and renal arteries can be reconstructed through branches; sufficient friction force is provided for graft anchoring and bridging through combined anchoring, branch selection is facilitated through a guide wire guiding area, and operation difficulty and the time are reduced. Therefore, the thoracico-abdominal aortic aneurysm is effectively treated, the operation time is shortened, and adverse reactions of contrast agents are reduced.

The present invention relates to the field of biological medicine and discloses an application of chrysophanol or its derivatives and oncolytic virus in preparing antitumor drugs. It is found for the first time that the chrysophanol or its derivatives can be used to prepare a synergistic agent with oncolytic virus in terms of anti-tumor effects. Also disclosed are a pharmaceutical composition comprising chrysophanol and oncolytic virus, a pharmaceutical package comprising chrysophanol and oncolytic virus, and the use of chrysophanol and oncolytic virus in treating tumors, in particular tumors insensitive to oncolytic virus.

The invention provides application of a pan-HDAC inhibitor to preparation of a drug used for treating uveal melanoma. The pan-HDAC inhibitor is PCI-24781 and has a molecular formula of C21H23N3O5; and the molecular structural formula of the pan-HDAC inhibitor is as shown in a formula I which is described in the specification. It is found for the first time that the PCI-24781 (abexinostat) can substantially inhibit cell growth of uveal melanoma and drug effect is improved with concentration increase. The objective of the invention is to provide a novel clinical treatment drug for uveal melanoma, and the novel clinical treatment drug can improve treatment effectiveness, prolong the life of a patient and enhance quality of life. A novel field is opened up in the invention.

The invention discloses application of EZH2 (enhancer of zeste homolog 2) inhibitor compounds in the preparation of drugs for treating eye melanoma; the EZH2 inhibitor compounds include GSK503, GSK343, EPZ005687 and EPZ-6438, having molecular formulas of C31H38N6O2, C31H39N7O2, C34H44N4O4 and C32H37N5O3, and molecular structural formulas which are shown in the description. The invention is intended to provide novel targets and drugs for the clinical treatment of eye melanoma, treatment effectiveness is improved, eye ball extraction rate is reduced, vision prognosis of patient is improved, and a novel field is exploited unprecedentedly.

An application of a transcription factor Spl specific inhibitor in preparation of medicines treating uveal melanoma is disclosed. The molecular formula of the inhibitor is C<52>H<76>O<24>, and the molecular structural formula of the inhibitor is shown as a formula I shown in the description. The application of mithramycin in preparation of medicines treating uveal melanoma is disclosed for the first time. The mithramycin can significantly inhibit growth and migration of uveal melanoma cells and can promote cell apoptosis. A novel treatment medicine is provided and can improve treatment effectiveness, prolong lifetime of patients and improve life quality. An unprecedented novel field is opened up.

The invention discloses an OAT inhibitor for the first time, and particularly Dimesna can improve the anti-tumor effect of oncolytic virus so as to improve the treatment effectiveness of the oncolyticvirus used as an anti-tumor drug. Cytological experiments prove that the M1 virus and the Dimesna are combined for use, so that morphological lesions of tumor cells can be remarkably caused, and theinhibition effect on the tumor cells is remarkably enhanced.

Aiming at the condition that the eye melanoma is lack of an effective drug for treatment, the invention firstly discovers that BACE2Inhibitor3l can obviously inhibit the growth of eye melanoma cells, and the drug effect is increased along with the increase of concentration. The invention provides a new treatment medicine for clinical treatment of eye melanoma, which improves the treatment effectiveness, prolongs the life of a patient, and improves the life quality. The invention develops a new field of the application of the BACE2Inhibitor3l in the treatment of the eye melanoma.

The invention relates to the field of lung rehabilitation equipment, and particularly discloses lung rehabilitation equipment based on respiration flow rate monitoring and abdominal pressure early warning, which comprises a respiration monitoring device, an intra-abdominal pressure monitoring device, a central processing unit and an abdominal pressure device, by monitoring the breathing condition of a patient and the intra-abdominal pressure condition of the patient, the central processing unit is adopted to control the abdominal pressure device to press the abdomen of the patient in a bionic breathing movement mode according to the breathing condition information of the patient and the intra-abdominal pressure information of the patient; according to the bionic breathing movement mode, the abdominal pressure device presses the abdomen of the patient according to the breathing condition of the patient, and pressing consistent with the breathing frequency of the patient is achieved. When the abdominal pressure device presses the abdomen of the patient, the abdominal pressure of the patient can be increased, and the diaphragm is promoted to lift upwards, so that the thorax and lung activity of the patient is increased, and the risks of decline of vital capacity and pulmonary infection of the patient caused by lying in bed are reduced.

The invention provides an intelligent foot correction customization method based on biomechanics. The method comprises the steps of collecting personal static foot data by a foot 3D scanner; collecting personal gait parameters by a gait detector; comparing the acquired data with standard big data owned by the cloud server, and judging the foot type and gait according to a comparison result; according to all existing foot and gait parameters, summarizing foot types and disease characteristics, designing a plurality of key models to form a 3D printing key model library, and screening key modelsmatched with individuals according to judgment results; connecting a 3D printer for production; and carrying out follow-up visit time design on individuals according to a judgment result. The intelligent foot correction customization method and system based on biomechanics can be applied to prevention, clinical diagnosis, rehabilitation therapy and sports science, the detection cost is reduced, the detection accuracy is improved, the user experience is optimized, the treatment effectiveness is improved, and more people can enjoy convenience brought by development of the large health industry.

The invention relates to a preparation method in which a crude medicine formula mainly based on natural plants as components is prepared into a medicament containing active officinal components by applying a unique pharmaceutical idea and a technical means, and particularly relates to a preparation method of a capsule for treating cardiovascular diseases. The preparation method of the capsule fortreating the cardiovascular diseases successively comprises the following steps: 1. respectively smashing 60g of ligusticum chuanxiong, 60g of radix salviae miltiorrhizae, 200g of dalbergia wood and 80g of borneol into fine powder for later use; 2. decocting 120g of ligusticum chuanxiong, 120g of radix salviae miltiorrhizae, 180g of purslane and 180g of homalomena occulta twice with water, wherein the first decocting time is 1.5 hours, and the second decocting time is 1 hour, filtering, mixing filtrates, concentrating the mixed filtrate to obtain a clear paste with a relative density of 1.10-1.20 at the temperature of 90 DEG C, adding ethanol so that ethanol content is 60%, standing for 48 hours, filtering, and recovering ethanol from the filtrate to obtain a thick paste the relative density of 1.31 at the temperature of 80 DEG C for later use; 3. adding the fine powder except borneol in the step 1 into the thick paste in the step 2, evenly mixing, and drying at the temperature below 80 DEG C, and smashing; and 4. adding the borneol fine powder in the step 1, evenly mixing, and encapsulating to obtain the capsule for treating the cardiovascular diseases.